PharmaJet develops needle-free injection devices that are user-friendly, inexpensive device platforms for fluid injection into the body without a needle.  Their patented technology is optimized for vaccine immunization – intramuscularly or intradermally. PharmaJet is the first and only World Health Organization (WHO) pre-qualified needle-free injection system. They have several key global partnerships in place, including WHO, the Serum Institute of India, GosZMP, and Seqirus.

RVC first invested in PharmaJet in 2015, and followed-on again in 2016.

Due Diligence Materials

  1. PharmaJet Executive Summary 1-Pager — April 2017
  2. PharmaJet Presentation Deck — May 2017
  3. PharmaJet Device Achievements and References— May 2017
  4. RVC Deal Leads –Why We Like the PharmaJet DealJune 2017
  5. PharmaJet Series F Term Sheet— June 2017

Investment Opportunity

Series F Available Now

PharmaJet is now raising a $5M Series F, preferred equity round. This comes on a $75M pre-money valuation.

Any interested RVC angels can join the PharmaJet Investment Group LLC by clicking the links below to invest